← SUPERNUS PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $210.1m |
$294.1m
+39.99%
|
$408.9m
+39.03%
|
$392.8m
-3.95%
|
$520.4m
+32.50%
|
$579.8m
+11.41%
|
$667.2m
+15.09%
|
$607.5m
-8.95%
|
$661.8m
+8.94%
|
$719.0m
+8.63%
|
$830.4m
+15.51%
|
|
| Interest Revenue (Expense), Net | — | — | — | — | $16.0m | $8.8m | — | — | — | — | — | |
| Cost of Revenue | $12.0m |
$15.2m
+26.94%
|
$15.4m
+0.93%
|
$16.7m
+8.49%
|
$52.5m
+214.88%
|
$75.1m
+43.09%
|
$87.2m
+16.20%
|
$83.8m
-3.95%
|
$77.9m
-7.01%
|
$74.6m
-4.29%
|
$99.0m
+32.82%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | — | $75.1m |
$87.2m
+16.20%
|
— | — | — | $99.0m | |
| Gross Profit (Calculated) | $203.0m |
$287.0m
+41.38%
|
$393.5m
+37.11%
|
$376.1m
-4.43%
|
$467.9m
+24.42%
|
$504.7m
+7.86%
|
$580.0m
+14.92%
|
$523.7m
-9.70%
|
$583.9m
+11.49%
|
$644.4m
+10.36%
|
— | |
| Research and Development Expense | $42.8m | $49.6m | $89.2m | $69.1m | $76.0m | $90.5m | $74.6m | $91.6m | $108.8m | $106.2m | $126.1m | |
| Selling, General and Administrative Expense | $106.0m | $137.9m | $159.9m | $158.4m | $200.7m | $304.8m | $377.2m | $336.4m | $321.6m | $485.6m | $560.9m | |
| Amortization of Intangible Assets | $1.3m | $6.9m | $5.2m | $5.2m | $15.7m | $30.0m | $82.6m | $82.4m | $78.0m | $89.5m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $54.2m |
$99.5m
+83.60%
|
$144.4m
+45.11%
|
$148.6m
+2.86%
|
$173.7m
+16.91%
|
$86.0m
-50.47%
|
$46.1m
-46.39%
|
($5.3m)
-111.42%
|
$81.7m
+1649.93%
|
($62.3m)
-176.27%
|
($55.4m)
+11.06%
|
|
| Interest Expense | $543k | $134k | $13.8m | $18.2m | $19.4m | $19.7m | — | — | — | — | $2.3m | |
| Interest Expense, Debt | — | — | — | — | — | — | $4.7m | $1.3m | $0 | $0 | $2.3m | |
| Interest Income, Other | — | — | — | $21.6m | $18.7m | — | — | — | — | — | $9.3m | |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | — | — | ($8k) | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $448k | $76k | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($15k) | — | — | ($1.1m) | ($5.0m) | ($12.9m) | $14.6m | $10.5m | $16.2m | $13.3m | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | $2.4m | $0 | $0 | $2.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | ($48.8m) | ($123.5m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $50.4m | $100.6m | $140.2m | $147.5m | $168.6m | $73.2m | $60.7m | $2.8m | $97.9m | ($49.0m) | ($123.5m) | |
| Current Income Tax Expense (Benefit) | — | — | ($600k) | — | — | — | — | — | — | ($15.7m) | ($13.6m) | |
| Income Tax Expense (Benefit) | ($40.9m) | $43.3m | $29.2m | $34.4m | $41.7m | $19.8m | $32k | $1.5m | $24.0m | ($10.5m) | ($13.6m) | |
| Net Income (Loss) Attributable to Parent | $91.2m |
$57.3m
-37.20%
|
$111.0m
+93.76%
|
$113.1m
+1.86%
|
$127.0m
+12.29%
|
$53.4m
-57.92%
|
$60.7m
+13.64%
|
$1.3m
-97.83%
|
$73.9m
+5512.84%
|
($38.5m)
-152.19%
|
($109.9m)
-185.05%
|
|
| Earnings Per Share, Basic | $1.84 | $1.13 | $2.13 | $2.16 | $2.41 | $1.01 | $1.13 | $0.02 | $1.34 | ($0.68) | ($1.92) | |
| Earnings Per Share, Diluted | $1.76 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | ($0.68) | ($1.92) | |
| Weighted Average Number of Shares Outstanding, Basic | 49.5m | 50.8m | 52.0m | 52.4m | 52.6m | 53.1m | 53.7m | 54.5m | 55.1m | 56.5m | 57.4m | |
| Weighted Average Number of Shares Outstanding, Diluted | 51.7m | 53.3m | 54.1m | 53.8m | 53.7m | 54.4m | 61.7m | 55.5m | 56.0m | 56.5m | 57.4m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $160.8m | $202.7m | $264.5m | $244.2m | $346.7m | $493.7m | $621.1m | $612.8m | $580.2m | $781.2m | — | |
| Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded | — | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | $0 | $0 | $0 | $54.9m |